Driving Innovation in Rapid AST in High-Resistance Settings

In regions where antimicrobial resistance (AMR) poses significant challenges, innovation in diagnostics is critical. Dr. Alberto Antonelli from the University of Florence shares promising findings from a study using the QuickMIC® system for ultra-rapid antimicrobial susceptibility testing (AST).

AMR is a growing global health crisis, responsible for prolonged hospital stays, increased mortality, and rising healthcare costs. Addressing this challenge requires not only new antibiotics but also advanced diagnostic tools that empower clinicians to make informed treatment decisions quickly.

The QuickMIC® system is transforming the way clinicians manage infections, particularly in high-resistance settings. Traditional AST methods can take up to 72 hours to deliver results, delaying crucial decisions on effective treatment. QuickMIC, however, provides precise minimum inhibitory concentration (MIC) values in just 2–4 hours.

Dr. Antonelli’s study highlights QuickMIC’s impact in tackling resistant Gram-negative bacteria such as Pseudomonas aeruginosa and Enterobacterales. These pathogens are notoriously difficult to treat, and timely diagnostics are essential to guiding effective therapy. The findings show how ultra-rapid AST supports targeted treatments, helping to combat resistance by preserving the efficacy of critical antibiotics and minimising the spread of multidrug-resistant organisms.

Discover how QuickMIC is revolutionising sepsis diagnostics and paving the way for better patient care.